Find News

Filter articles

Applied Filters

Showing 691 to 700 of 730 results

C5 Congress: Patenting natural products after Myriad


Speaking at Wednesday's C5 Congress on Biotech and Pharma Patenting in London, Michael McGraw, a partner from Fitzpatrick, Cella, Harper and Scinto in New York, considered the line that separates natural and man-made products.

C5 Congress: Myriad decision "will not" affect patenting in Europe


Aliki Nichogiannopoulou, director of biotechnology at the European Patent Office, outlined best practices for patenting antibodies at the office while speaking at the 25th C5 Congress on Biotech and Pharma Patenting in London on Wednesday.

Orrick expands IP team


Orrick Herrington & Sutcliffe LLP has expanded its IP group and hired Grace Pan as partner.

Medical company in trade secrets dispute with employee


Medical company Scion Biomedical Inc has launched a lawsuit accusing a senior employee of breaching trade secrets to file a patent for her new start-up company.

Senate IP counsel set for Covington switch


Aaron Cooper, chief counsel for IP and antitrust law in the US Senate Judiciary Committee, is to join law firm Covington & Burling LLP.

Biologics milestone as court denies declaratory judgment

US13-11-2013Legal developments

The US District Court for the Northern District of California has dismissed biosimilar maker Sandoz’s motion for declaratory judgment that its etanercept product does not infringe biopharmaceutical company Amgen’s arthritis drug Enbrel.

Syntrix celebrates US damages ruling


A federal court has upheld a ruling that biotech company Illumina should pay rival Syntrix $115 million and an 8 percent running royalty rate for patent infringement.

Myriad decision applied in diagnostic claims case

US06-11-2013Legal developments

The US District Court for the Northern District of California has found that diagnostic claims covering conventional detection methods do not make the use of a natural phenomenon patent eligible.

Pfizer wins IL-13 priority over Sanofi


The US Court of Appeals for the Federal Circuit affirmed on Tuesday that pharmaceutical company Pfizer can patent a DNA polynucleotide ahead of rival Sanofi-Aventis.

Novartis petitions FDA on biosimilar naming convention


Novartis has urged the FDA to allow biosimilars to bear the same international nonproprietary names as their reference products.

Showing 691 to 700 of 730 results